Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Sanderzon Mar 30, 2018 9:50pm
68 Views
Post# 27809520

RE:THE BASHER has switched back to soft bashing,

RE:THE BASHER has switched back to soft bashing, Hey man. I wasn't bashing, at least not intentionally. I'm not sure if you even read my post, but I was saying that its the MARKET that might not price this where it should be. However, I will hang on and see what the future brings. I can't accumulate more than what I already have because I'm tapped out. But I'll hang on and see if this surprises me. Because I was just giving my opinion and opinions can be right or wrong.
ColonelSanderz wrote: with the re-appearance of Sanderz and AlgAlg.  All LONGS, log in, and hit the Report Abuse button for both Sanderz and AlgAlg. 

Back to the soft bashes, THE BASHER knows that the warrants are almost done and that the supply side skew is quickly coming to an end.  In addition, the word is getting out about the potential BLOCKBUSTER called ATB-346, brought to you by Antibe Therapeutics.  As such, the "fear posts" that THE BASHER was trying to use won't stick now.  So, THE BASHER is trying to use the soft bash to subtly insinuate himself into LONG conversations and trying to suggest that continuing to hold, now that we're hitting a horizontal trading pattern until the next event, is questionable.  Well, here's a shocking proposition:  investors hold and the envious want their shares!

THE BASHER is always trying: like the serpent wrapped around the apple tree.

Well, LONGS, don't eat his shite sandwich.  ATE has the potential, the REAL potential, to be trading at DOLLARS PER SHARE within the next 6-24 months.  And as other LONGS have already pointed out:  .435 per share in March is a lot higher than .08 per share back in October.  That's a pretty amazing climb, and it's just starting!

JMO, ColonelSanderz


Bullboard Posts